Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: Impact on neointimal proliferation and healing

Open Heart

Volumn 1, Issue 1, 2014, Pages

  Granada, Juan F ^a   Stenoien, Mark ^b   Buszman, Piotr P ^a   Tellez, Armando ^a   Langanki, Dan ^b   Kaluza, Greg L ^a   Leon, Martin B ^c   Gray, William ^c   Jaff, Michael R ^d   Schwartz, Robert S ^e  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b MEDRAD Interventional ^*  (United States)

^c Department of Medicine   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ABDOMINAL AORTA; ANGIOPLASTY CATHETER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON; BALLOON DILATATION; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY INJURY; DOMESTIC PIG; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RETENTION; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; FIBRIN DEPOSITION; IN VIVO STUDY; IN-STENT RESTENOSIS; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PACLITAXEL COATED BALLOON; PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; WOUND HEALING;

EID: 84984633429     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2014-000117     Document Type: Article

References (34)

1. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113-24.
2. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-99.
3. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118:1358-65.
4. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 2012;60:2473-80.
5. Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv 2012;5:392-400.
6. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-14.
7. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
8. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.
9. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
10. Posa A, Hemetsberger R, Petnehazy O, et al. Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries. Coron Artery Dis 2008;19:243-7.
11. Radke PW, Joner M, Joost A, et al. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention 2011;7:730-7.
12. Yeh TK, Lu Z, Wientjes MG, et al. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005;22:867-74.
13. Institute of Laboratory Animal Resources NRC. Principles of care of laboratory animals. NIH Publication, 1996:85-23.
14. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
15. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009;119:2986-94.
16. Ferns GA, Avades TY. The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 2000;81:63-88.
17. Serruys PW, Sianos G, Abizaid A, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253-60.
18. Henry TD, Schwartz RS, Hirsch AT. "POBA Plus": will the balloon regain its luster? Circulation 2008;118:1309-11.
19. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003;42:1415-20.
20. Stampfl U, Radeleff B, Sommer C, et al. Paclitaxel-induced arterial wall toxicity and inflammation: part 2 - long-term tissue response in a minipig model. J Vasc Interv Radiol 2009;20:1608-16.
21. Radeleff B, Lopez-Benitez R, Stampfl U, et al. Paclitaxel-induced arterial wall toxicity and inflammation: tissue uptake in various dose densities in a minipig model. J Vasc Interv Radiol 2010;21:1262-70.
22. Cremers B, Milewski K, Clever YP, et al. Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis. Catheter Cardiovas Interv 2012;80:603-10.
23. Miller KM. A drug-eluting stent case study: TAXUS Express2 - from development to approval. New England Chapter Parental Drug Association Workshop. 2004.
24. Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010;96:1291-6.
25. Innocenti F, Danesi R, Di Paolo A, et al. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab Dispos 1995;23:713-17.
26. Eiseman JL, Eddington ND, Leslie J, et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994;34:465-71.
27. Fetterly GJ, Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 2003;5:E32.
28. Gustafson DL, Long ME, Bradshaw EL, et al. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Cancer Chemother Pharmacol 2005;56:248-54.
29. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969-76.
30. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
31. Levin AD, Vukmirovic N, Hwang CW, et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA 2004;101:9463-7.
32. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res 2000;86:879-84.
33. Balakrishnan B, Dooley JF, Kopia G, et al. Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J Control Release 2007;123:100-8.
34. Pourroy B, Honore S, Pasquier E, et al. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 2006;66:3256-63.